VERAXA Biotech AG (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.
The company's BiTAC platforms represent a significant advancement in antibody-based therapeutics. The BiTAC-ADC platform combines bispecific antibodies with antibody-drug conjugates (ADCs) to enable tumor-restricted activation, potentially reducing the systemic toxicity that often limits traditional chemotherapy. Meanwhile, the BiTAC-TCE platform focuses on bispecific T cell engagers, which redirect immune cells to attack tumor cells. Together, these platforms aim to address critical unmet needs in oncology by enhancing efficacy while improving safety profiles.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
The presentation of data at major conferences like AACR and the upcoming discussions at BIO underscore the growing interest in bispecific platforms. For investors and industry observers, the ability of VERAXA to secure partnerships will be a key indicator of the commercial potential of its platforms. The company's newsroom at http://ibn.fm/VRXA provides the latest updates and information on VRXA.
The full press release is available at https://ibn.fm/1je4AA. As the biotechnology sector continues to evolve, platforms like BiTAC that offer precision targeting and reduced side effects could become increasingly important in the development of safer and more effective cancer therapies.
